Executive Summary

• Hydreight Technologies reported ~295,000 VSDHOne product orders and a 49% YoY increase in nurse sign‑ups (198 new nurses July–Sept vs. 133 prior year).
• The company closed an oversubscribed CA$11.5 million convertible debenture on September 4, 2025, raising cash to approximately CA$18.7 million as of October 22, 2025.
• Hydreight earned multiple recognitions—including #25 on Deloitte’s 2025 Technology Fast 50 (Canada) and a finalist for the BC Tech Association’s Company‑of‑the‑Year award—underscoring rapid revenue growth and market leadership.

Key Details

• Product & Network Growth
• ~295,000 VSDHOne product orders processed July–Sept 2025 across GLP‑1 weight‑management, hormone therapy, NAD, hair restoration, genetic testing, Ondanestron, etc.
• Nurse network expansion: 198 new sign‑ups (July–Sept 2025) vs. 133 same period FY24 (+49% YoY); 593 total sign‑ups YTD 2025 vs. 364 YTD 2024 (+63% YoY).

• Pharmacy orders (excluding VSDHOne) up ~72% YoY, reflecting broader adoption across wellness verticals.

• Financing

• Convertible debenture financing: CA$11.5 million, oversubscribed; closed September 4, 2025.

• Resulting cash balance: ≈ CA$18.7 million as of October 22, 2025.

• Operational & Technology Initiatives

• Integration of additional 503A/503B pharmacy partners to boost capacity, fulfillment speed, and margin potential.
• Upcoming release of VSDHOne V2, an enhanced telehealth platform with greater automation, scalability, and modular functionality.

• Ongoing national rollout of Dr. Franklin Joseph’s GLP‑1 program and expansion of direct‑to‑consumer (D2C) wellness offerings on VSDHOne.

• M&A Pipeline

• Active evaluation of profitable multi‑state wellness and digital‑health operators that can be scaled nationally via the VSDHOne platform.

• Recognition & Awards

• 25 on Deloitte’s 2025 Technology Fast 50 (Canada) for revenue growth 2021‑2024.

• Previously #56 on Deloitte’s 2024 Technology Fast 500 (U.S.).
• Listed as a Top 50 TSX Venture Exchange Company for 2024.

• Finalist for BC Tech Association’s 2025 Company of the Year – Scale Award and EY Entrepreneur of the Year Canada Pacific Region finalist.

• Investor Relations Activities

• Analyst coverage initiated by Maxim Group and Beacon Securities.

• Participation in multiple investor events (CEM Muskoka Capital Event, Smallcap Discoveries, Planet MicroCap Showcase) with presentations and one‑on‑one meetings on Oct 22‑23, 2025.

• Outlook

• Entering Q4 2025 with strong operational momentum, solid cash position, and focus on profitable expansion of GLP‑1, D2C, and pharmacy network initiatives.

Notable Quotes

“Hydreight’s recognition by Deloitte as one of Canada’s fastest‑growing technology companies is a validation of our model and execution,” said Shane Madden, CEO.
“Our performance from July to September demonstrates the strength and scalability of our compliant healthcare infrastructure. With approximately CA$18.7 million in cash, we’re well positioned to accelerate growth across our GLP‑1, D2C and pharmacy network initiatives while continuing to execute profitably and responsibly.”